Portal:COVID-19/FeaturedPathways
From WikiPathways
(Difference between revisions)
(→SARS-CoV-2 Pathways) |
|||
Line 24: | Line 24: | ||
|width=100px|{{#pwImage:Pathway:WP4904|250px||LDLRAD4 pathway in COVID-19}} | |width=100px|{{#pwImage:Pathway:WP4904|250px||LDLRAD4 pathway in COVID-19}} | ||
|width=100px|{{#pwImage:Pathway:WP4936|250px||Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP4936|250px||Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens)}} | ||
+ | |- | ||
+ | |} | ||
+ | |||
+ | == Other coronaviruses: MERS, SARS-CoV, etc == | ||
+ | |||
+ | {| style="margin: 10px; background-color:#AFDCDE" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4853|250px||Coronavirus lipid metabolism}} | ||
+ | Lipid metabolism alternations that are related to infection by the corona virus. | ||
+ | |width=100px|{{#pwImage:Pathway:WP4863|250px||Host-pathogen interaction of human corona viruses - autophagy}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4864|250px||Host-pathogen interaction of human corona viruses - apoptosis}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4912|250px||SARS coronavirus and innate immunity}} | ||
+ | |- | ||
+ | |} | ||
+ | {| style="margin: 10px; background-color:#AFDCDE" | ||
+ | |width=100px|{{#pwImage:Pathway:WP4861|250px||ER stress response in Coronavirus infection}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4799|250px||Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4877|250px||Host-pathogen interaction of human corona viruses - MAPK signaling}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4880|250px||Host-pathogen interaction of human corona viruses - Interferon induction}} | ||
+ | |- | ||
+ | |} | ||
+ | |||
+ | == More about ACE2 == | ||
+ | |||
+ | {| style="margin: 10px; background-color:#AFDCDE" | ||
+ | |width=100px|{{#pwImage:Pathway:WP554|250px||ACE Inhibitor Pathway}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP2729|250px||Metabolism of Angiotensinogen to Angiotensins (Reactome)}} | ||
|- | |- | ||
|} | |} |
Revision as of 19:53, 9 September 2020
SARS-CoV-2 Pathways
Image does not exist Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. |
Image does not exist SARS-CoV-2 includes a novel Orf10 that interacts with muliple members of the Cullin 2 ubiquitin ligase complex. |
Image does not exist The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. |
Image does not exist |
Image does not exist Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. |
Image does not exist |
Image does not exist Experimental pathway to investigate overlap of virus-host interaction and adverse outcome pathways |
Image does not exist Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis |
Image does not exist |
Image does not exist |
Other coronaviruses: MERS, SARS-CoV, etc
Image does not exist Lipid metabolism alternations that are related to infection by the corona virus. |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
More about ACE2
Image does not exist |
Image does not exist |